Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 15/20 | 0.67 |
| ▸ | MMP3 | P08254 | 14/20 | 0.67 |
| ▸ | MMP13 | P45452 | 14/20 | 0.67 |
| ▸ | MMP7 | P09237 | 13/20 | 0.67 |
| ▸ | MMP9 | P14780 | 13/20 | 0.67 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8207819 | 0.79 | MMP1 (0.59) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL18711921 | 0.75 | PKM (0.76) | PKM | |
| SCHEMBL17800359 | 0.75 | ALDH1A1 (0.46) | — | |
| SCHEMBL2440048 | 0.73 | MMP1 (0.66) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL2439281 | 0.73 | MMP1 (0.66) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL16430933 | 0.72 | MMP1 (0.53) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL7472679 | 0.71 | MMP1 (0.71) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL6267756 | 0.71 | MMP1 (0.60) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL27770182 | 0.70 | MMP1 (0.62) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL10282072 | 0.70 | POLB (0.37) | MMP1MMP3MMP13MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | MMP1 511/4885MMP3 527/4885MMP13 451/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | MMP1 626/4885MMP3 650/4885MMP13 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.